6531 POSTER XPD 312 single nucleotide polymorphism (SNP) predicts survival in stage IIIA–B non-small-cell lung cancer (NSCLC) patients (pts) < 59 years (y) treated with chemotherapy followed by surgery

C.Santarpia; P.Garrido; J.L.Gonzalez-Larriba; P.Azagra; F.Cardenal; J.L.Ramirez; I.De Aguirre; M.Sanchez-Ronco; M.Taron; R.Rosell

首页> 外文期刊>European Journal of Cancer Supplements >6531 POSTER XPD 312 single nucleotide polymorphism (SNP) predicts survival in stage IIIA–B non-small-cell lung cancer (NSCLC) patients (pts) < 59 years (y) treated with chemotherapy followed by surgery

【24h】

6531 POSTER XPD 312 single nucleotide polymorphism (SNP) predicts survival in stage IIIA–B non-small-cell lung cancer (NSCLC) patients (pts) < 59 years (y) treated with chemotherapy followed by surgery

机译：6531 POSTER XPD 312单核苷酸多态性（SNP）预测IIIA–B期非小细胞肺癌（NSCLC）患者（pts）<59岁（y）接受化疗然后手术治疗的生存率

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
C.Santarpia; P.Garrido; J.L.Gonzalez-Larriba; P.Azagra; F.Cardenal; J.L.Ramirez; I.De Aguirre; M.Sanchez-Ronco; M.Taron; R.Rosell;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 6528 POSTER Role of ERCC1, XRCC3, Aurora A and TGFBR1 gene single nucleotide polymorphisms (SNP) and CHFR and 14-3-3s methylation in a customized cisplatin (cis) trial based on ERCC1 mRNA levels in stage IV non-small-cell lung cancer (NSCLC) patients (pts) [J] . M.Taron, M.Cobo, L.Isla, European Journal of Cancer Supplements . 2007,第4期

机译：6528在基于IV期非小细胞肺的ERCC1 mRNA水平的定制顺铂（cis）试验中，ERCC1，XRCC3，Aurora A和TGFBR1基因单核苷酸多态性（SNP）和CHFR和14-3-3s甲基化的作用癌症（NSCLC）患者（pts）
2. 6576 POSTER Extent of mediastinal lymph-nodes resection as prognostic factor for survival in stage I–IIIA non-small-cell lung cancer (NSCLC) patients undergone surgery: a retrospective analysis of a mono-institutional series [J] . E.Bria, G.Alessandrini, P.Visca, European Journal of Cancer Supplements . 2007,第4期

机译：6576 POSTER纵隔淋巴结切除的程度是I–IIIA期非小细胞肺癌（NSCLC）患者接受手术的生存率的预后因素：单机构系列的回顾性分析
3. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. [J] . Ryu JS, Hong YC, Han HS, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2004,第3期

机译：ERCC1和XPD多态性与顺铂联合化疗治疗的非小细胞肺癌患者生存率的关系。
4. Does Sex Make a Difference in Survival of Patients Undergoing Resection for Early Stage Non-Small Cell Lung Cancer (NSCLC)? [C] . Steven J.Jubelirer, Nicole L.Varela, Christine A.Welch, 21st international conference on screening for lung cancer . 2009

机译：性别对早期非小细胞肺癌（NSCLC）切除患者的生存率有影响吗？
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy [O] . Ling Zhang, Guanghui Gao, Xuefei Li, -1

机译：单核苷酸多态性（sNp）和晚期非小细胞肺癌患者的毒性化疗治疗之间的关联
7. P3-137: XPD 312 single nucleotide polymorphism (SNP) predicts survival in stage IIIA–B non–small–cell lung cancer (NSCLC) patients (p) <59 years (y) treated with chemotherapy followed by surgery [O] . Carmen Santarpia, José-Luis González-Larriba, Pilar Azagra, 2007

机译：P3-137：XPD 312单核苷酸多态性（SNP）预测IIIA-B阶段 - B非小细胞肺癌（NSCLC）患者的存活（P）<59岁（Y），然后进行手术治疗

6531 POSTER XPD 312 single nucleotide polymorphism (SNP) predicts survival in stage IIIA–B non-small-cell lung cancer (NSCLC) patients (pts) < 59 years (y) treated with chemotherapy followed by surgery

著录项

相似文献

相关主题

期刊订阅